Orexigen Therapeutics Inc. announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA).
via Get Fit Bookmark http://ift.tt/1qO1opH
via Tumblr http://ift.tt/1oShvQ6
No comments:
Post a Comment